The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

AbbVie ABBV announced that the FDA has issued a complete response letter (CRL) to the biologics license application (BLA) ...

By Padmanabhan Ananthan April 23 (Reuters) - AbbVie said on Thursday the U.S. Food and Drug Administration has declined to ...

AbbVie plans to join many other large drugmakers in having major operations in North Carolina's Triangle region.

AbbVie Inc. ABBV shares are down during Friday’s premarket session following a Complete Response Letter (CRL) from the FDA ...

AbbVie has tapped North Carolina as the location for a new $1.4bn manufacturing site as part of its $100bn US manufacturing ...

AbbVie (NYSE:ABBV) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The ...

April 22 (Reuters) - AbbVie will invest $1.4 billion to build a manufacturing campus in North Carolina, the drugmaker said on ...

The regulator has sent a complete response letter (CRL) to AbbVie for trenibotulinumtoxinE (TrenibotE), a follow-up to its ...

Gov. Josh Stein announced AbbVie Inc., one of the world's largest biopharmaceutical companies, is coming to Durham.

The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.

Biopharma company AbbVie plans to bring 730 jobs to Durham County as part of $1.4 billion manufacturing investment. State ...